title: FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease.
abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been extensively used worldwide for both chronic and acute musculoskeletal and inflammatory conditions. Extensive evidence has linked NSAID use with adverse cardiovascular events. This review article aims to review the existing evidence on the risk of cardiovascular and coronary events in both selective and nonselective NSAIDs, the time course of NSAIDs associated with cardiovascular risk, and specific populations that may be at increased risk.
authors.affiliation: Department of Cardiology, Northwell Health System, Hofstra Northwell School of Medicine, Manhasset, NY.
authors.forename: Preethi
authors.initials: P
authors.lastname: Pirlamarla
authors.affiliation: Heart & Vascular Institute, Lenox Hill Hospital, Department of Cardiology, Northwell Health System, Hofstra Northwell School of Medicine, New York, NY. Electronic address: rbond12@northwell.edu.
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Bond
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D061214:Patient Safety; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal
keywords: COX-2 inhibitors; Cardiovascular disease; Cardiovascular risk; Coronary artery disease; Nonselective NSAIDs; Nonsteroidal anti-inflammatory drugs; Rheumatologic disease